Ubiquitin-mediated interaction of p210 BCR/ABL with β-catenin supports disease progression in a murine model for chronic myelogenous leukemia

被引:3
|
作者
Chen, Ru
Hu, Tinghui
Mahon, Gwendolyn M.
Tala, Ilona
Pannucci, Nicole L.
Ozer, Harvey L.
Whitehead, Ian P.
机构
[1] Univ Med & Dent New Jersey, Dept Microbiol & Mol Genet, Newark, NJ 07103 USA
[2] Univ Med & Dent New Jersey, New Jersey Med Sch, Univ Hosp Canc Ctr, Newark, NJ 07103 USA
关键词
HEMATOPOIETIC STEM-CELLS; CHRONIC MYELOID-LEUKEMIA; MYELOPROLIFERATIVE DISEASE; SORTING COMPLEX; BCR; ONCOGENE; DOMAIN; MICE; PROTEIN; TRANSFORMATION;
D O I
10.1182/blood-2013-01-481184
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
We have identified a ubiquitin-binding domain within the NH2-terminal sequences of p210 BCR/ABL and determined that the binding site co-localizes with the binding site for beta-catenin. The domain does not support the auto-or trans-kinase activity of p210 BCR/ABL or its ability to interact with GRB2 and activate ERK1/2 signaling. Expression of p210 BCR/ABL, but not a beta-catenin-binding mutant, in hematopoietic cells is associated with the accumulation of p-beta-catenin (Tyr654) and increased TCF/LEF-mediated transcription. In a bone marrow transplantation model, the interaction between beta-catenin and p-beta-catenin (Tyr654) is detectable in mice transplanted with p210 BCR/ABL, but not the mutant. Whereas mice transplanted with p210 BCR/ABL exhibit myeloid disease with expansion of monocytes and neutrophils, mice transplanted with the mutant predominantly exhibit expansion of neutrophils, polycythemia, and increased lifespan. The increased disease latency is associated with expansion of megakaryocyte-erythrocyte progenitors, a decrease in common myeloid progenitors, and reduced beta-catenin signaling in the bone marrow of the diseased mice. These observations support a model in which p210 BCR/ABL may influence lineage-specific leukemic expansion by directly binding and phosphorylating beta-catenin and altering its transcriptional activity. They further suggest that the interaction may play a role in chronic phase disease progression.
引用
收藏
页码:2114 / 2124
页数:11
相关论文
共 50 条
  • [21] Glucose transport regulation by p210 Bcr-Abl in a chronic myeloid leukaemia model
    Bentley, J
    Walker, I
    McIntosh, E
    Whetton, AD
    Owen-Lynch, PJ
    Baldwin, SA
    BRITISH JOURNAL OF HAEMATOLOGY, 2001, 112 (01) : 212 - 215
  • [22] THE CHRONIC MYELOGENOUS LEUKEMIA SPECIFIC P210-PROTEIN IS THE PRODUCT OF THE BCR/ABL HYBRID GENE
    BEN-NERIAH, Y
    DALEY, GQ
    MESMASSON, AM
    WITTE, ON
    BALTIMORE, D
    SCIENCE, 1986, 233 (4760) : 212 - 214
  • [23] BCR-ABL1 p210 screening for chronic myeloid leukemia in patients with peripheral blood cytoses
    Fenu, Elena
    O'Neill, Stacey S.
    Insuasti-Beltran, Giovanni
    INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, 2021, 43 (06) : 1458 - 1464
  • [24] Imatinib-resistant activation of β-catenin by BCR-ABL in a murine model of chronic myelogenous leukemia stem cells.
    Minami, Yosuke
    Stuart, Scott
    Ikawa, Tomokatsu
    Banno, Asoka
    Hunton, Irina
    Willert, Karl
    Murre, Cornelis
    Jamieson, Catriona
    Wang, Jean Y. J.
    BLOOD, 2006, 108 (11) : 603A - 603A
  • [25] Correlation of p210 BCR-ABL transcript variants with clinical, parameters and disease outcome in 45 chronic myeloid leukemia patients
    Al-Achkar, Walid
    Moassass, Faten
    Youssef, Nagham
    Wafa, Abdulsamad
    JOURNAL OF BUON, 2016, 21 (02): : 444 - 449
  • [26] Coexistence of P190 and P210 BCR/ABL transcripts in chronic myeloid leukemia blast crisis resistant to imatinib
    Zhao Junmei
    Yu Fengkuan
    Song Yongping
    Fang Baijun
    Liu Yuzhang
    Liu Lina
    Zhang Qinglan
    SPRINGERPLUS, 2015, 4
  • [27] INDUCTION OF CHRONIC MYELOGENOUS LEUKEMIA IN MICE BY THE P210BCR/ABL GENE OF THE PHILADELPHIA-CHROMOSOME
    DALEY, GQ
    VANETTEN, RA
    BALTIMORE, D
    SCIENCE, 1990, 247 (4944) : 824 - 830
  • [28] TYRPHOSTIN INDUCED GROWTH-INHIBITION - CORRELATION WITH EFFECT ON P210(BCR-ABL) AUTOKINASE ACTIVITY IN K562 CHRONIC MYELOGENOUS LEUKEMIA
    KAUR, G
    GAZIT, A
    LEVITZKI, A
    STOWE, E
    COONEY, DA
    SAUSVILLE, EA
    ANTI-CANCER DRUGS, 1994, 5 (02) : 213 - 222
  • [29] APPEARANCE OF ACUTE LEUKEMIA-ASSOCIATED P190BCR-ABL IN CHRONIC MYELOGENOUS LEUKEMIA MAY CORRELATE WITH DISEASE PROGRESSION
    DHINGRA, K
    TALPAZ, M
    KANTARJIAN, H
    KU, S
    ROTHBERG, J
    GUTTERMAN, JU
    KURZROCK, R
    LEUKEMIA, 1991, 5 (03) : 191 - 195
  • [30] A model of human p210bcr/ABL-mediated chronic myelogenous leukemia by transduction of primary normal human CD34+ cells with a BCR/ABL-containing retroviral vector
    Zhao, RC
    Jiang, YH
    Verfaillie, CM
    BLOOD, 2001, 97 (08) : 2406 - 2412